X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VBP15 (vamorolone) is an investigational drug candidate with a mode of action based on binding to the same receptor as corticosteroids but modifying its downstream activity and as such is considered a dissociative anti-inflammatory drug.
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: VBP15
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Santhera Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Vamorolone is an investigational drug candidate with a mode of action based on binding to the same receptor as corticosteroids but modifying its downstream activity and as such is considered a dissociative anti-inflammatory drug.
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: VBP15
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Santhera Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
VBP15 (vamorolone) is a drug candidate with a mode of action that binds to the same receptor as corticosteroids but modifies its downstream activity and as such is considered a dissociative anti-inflammatory drug.
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: VBP15
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Santhera Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
VBP15 (Vamorolone) is a drug candidate with a novel mode of action that binds to the same receptor as corticosteroids but modifies its downstream activity and as such is a dissociative agonist.
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: VBP15
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Santhera Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
The trial met its primary endpoint of superiority in change of time to stand from supine position (TTSTAND) velocity with vamorolone, a dissociative agonist 6 mg/kg/day versus placebo (p=0.002) at 24 weeks (period 1).
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: VBP15
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Santhera Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
Evidence of clinical efficacy and safety of vamorolone in patients with DMD is based on the positive outcome of the pivotal Phase 2b VISION-DMD study and additional Phase 2a data covering a vamorolone treatment period of up to 30 months.
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: VBP15
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Santhera Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
Vamorolone could prove to be a promising alternative to the existing corticosteroids that are currently the standard of care for children and adolescents with DMD.
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: VBP15
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Santhera Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2021
Details:
Vamorolone is a first-in-class dissociative steroid which retains the anti-inflammatory activity of corticosteroids while decreasing the deleterious side effects used against Duchenne muscular dystrophy.
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: VBP15
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Santhera Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2021
Details:
In this trial, vamorolone demonstrated efficacy versus placebo over a three-fold dose range of 2 to 6 mg/kg/day versus placebo (p=0.002) and showed for both doses a favorable safety and tolerability profile versus the active control arm of prednisone 0.75mg/kg/day.
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: VBP15
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Santhera Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
Details:
The study met its primary endpoint of superiority in change of time to stand from supine positioning to standing (TTSTAND) velocity with vamorolone 6mg/kg/day, versus placebo.
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: VBP15
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Santhera Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
